Use of 5-0 Fast Absorbing Gut versus 6-0 Fast Absorbing Gut during cutaneous wound closure on the head and neck: A randomized evaluator-blinded split-wound comparative effectiveness trial - 18/05/19
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Background |
Absorbable suture material (Fast Absorbing Gut [FG], Ethicon, Somerville NJ) is often used for patient convenience; however, the optimal diameter of FG sutures is debatable.
Objective |
To determine whether the use of 6-0 FG during repair of linear cutaneous surgery wounds on the head and neck improves scar cosmesis compared with the use of 5-0 FG.
Methods |
This was a prospective, randomized, split-scar intervention in patients undergoing repair of linear cutaneous wounds on the head and neck. The scar was assessed 3 months after surgery via the Physician Observer Scar Assessment Scale (POSAS), a validated instrument.
Results |
The difference in the sum of the POSAS component scores for 6-0 FG (12.03) compared with that for 5-0 FG (13.11) was not statistically significant (P = .26). Observer overall opinion was similar for both interventions, at 2.49 for 6-0 FG vs 2.64 for 5-0 FG (P = .54). The difference in the number of complications in the 5-0 FG group (15) vs the 6-0 FG group (10) was not statistically significant (P = .40).
Limitations |
Single-center study with wounds limited to the head and neck in white individuals, with a predominance of men.
Conclusion |
For linear repair of cutaneous wounds, 6-0 FG was not statistically different for cosmetic outcomes, scar width, and complications compared with 5-0 FG.
Le texte complet de cet article est disponible en PDF.Key words : 5-0, 6-0, cutaneous closure technique, cutaneous surgery, Fast Absorbing Gut, scar evaluation, suture caliber, suture diameter, suture size
Abbreviations used : FG, POSAS
Plan
Drs Pourang and Crispin contributed equally to this article. |
|
Funding sources: This project was supported by the National Center for Advancing Translational Sciences and National Institutes of Health grant UL1-TR-000002, funding the REDCap database used for management of the study's data. |
|
Conflicts of interest: The authors have no relevant financial interests to report. Dr Armstrong served as an investigator or consultant, or both, to AbbVie, Janssen, Lilly, Pfizer, UCB, Dermira, Ortho Dermatologics, Sanofi Genzyme, Regeneron, BMS, Dermavant, Science 37, and Modernizing Medicine. Dr Sivamani serves as a scientific advisor to Dermveda and LearnSkin and as a consultant to Burt's Bees and Dermala. Drs Pourang, Crispen, Clark, and Eisen have no conflicts of interest to disclose. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?